The Importance of Real-World Evidence in Understanding Influenza Vaccine Effectiveness
DOI:
https://doi.org/10.7175/fe.v23i1.1522Keywords:
influenza vaccine, Vaccine effectiveness, Real-world evidenceReferences
Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol 2018; 16: 47-60; https://doi.org/10.1038/nrmicro.2017.118
World Health Organization - Regional Office for Europe. Influenza - estimating burden of disease. Available at: https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/seasonal-influenza/burden-of-influenza (last accessed on January 2022)
D’Angiolella LS, Lafranconi A, Cortesi PA, et al. Costs and effectiveness of influenza vaccination: a systematic review. Ann Ist Super Sanita 2018; 54: 49-57; https://doi.org/10.4415/ANN_18_01_10
Treanor JJ. Influenza (Including Avian Influenza and Swine Influenza). In: Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases (Eighth Edition). W.B. Saunders, 2015: Pages 2000-2024.e6; https://doi.org/10.1016/B978-1-4557-4801-3.00167-3
US Centers for Disease Control and Prevention – National Center for Immunization and Respiratory Diseases (NCIRD). How Flu Vaccine Effectiveness and Efficacy are Measured. Available at: https://www.cdc.gov/flu/vaccines-work/effectivenessqa.htm (last accessed on January 2022)
Balasingam S, Wilder-Smith A. Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. Int J Infect Dis 2016; 49: 18-29; https://doi.org/10.1016/j.ijid.2016.05.013
Boni MF. Vaccination and antigenic drift in influenza. Vaccine 2008; 26: C8-14; https://doi.org/10.1016/j.vaccine.2008.04.011
US Centers for Disease Control and Prevention - National Center for Immunization and Respiratory Diseases (NCIRD). Influenza Vaccines for Older Adults. Advisory Committee on Immunization Practices (ACIP) January 12, 2022
Jayasundara K, Soobiah C, Thommes E, et al. Natural attack rate of influenza in unvaccinated children and adults: a meta-regression analysis. BMC Infectious Diseases 2014; 14: 670; https://doi.org/10.1186/s12879-014-0670-5
Tokars JI, Rolfes MA, Foppa IM, et al.. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine 2018; 36: 7331-7; https://doi.org/10.1016/j.vaccine.2018.10.026
Flannery B, Fry AM. Comparing Influenza Vaccine Types: The Path Toward Improved Influenza Vaccine Strategies. J Infect Dis 2019; 220: 1237-9; https://doi.org/10.1093/infdis/jiy717
Halloran ME, Struchiner CJ, Longini IM. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997; 146: 789-803; https://doi.org/10.1093/oxfordjournals.aje.a009196
Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials 2017; 18: 122; https://doi.org/10.1186/s13063-017-1870-2
Martini N, Trifirò G, Capuano A, et al. Expert opinion on Real-World Evidence (RWE) in drug development and usage. Pharmadvances 2020; 2: 41-50; https://doi.org/10.36118/pharmadvances.02.2020.01
Uyeki TM. High-risk Groups for Influenza Complications. JAMA 2020; 324: 2334; https://doi.org/10.1001/jama.2020.21869
Ponticelli D, Madotto F, Conti S, et al. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up. Intern Emerg Med 2021: 1-6; https://doi.org/10.1007/s11739-021-02857-y
Ponticelli D, Antonazzo IC, Caci G, et al. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months. J Travel Med 2021; 28: taab173; https://doi.org/10.1093/jtm/taab173
Ferrara P, Antonazzo IC, Polosa R. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: A 3-month follow-up-Reply. Intern Emerg Med 2022; 17: 313-14; https://doi.org/10.1007/s11739-021-02911-9
US Food and Drug Administration. Real-World Evidence. FDA: 2022. Available at: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence (last accessed on January 2022)
Reynolds MW, Bourke A, Dreyer AN. Considerations when evaluating real-world data quality in the context of fitness for purpose. Pharmacoepidemiol Drug Saf 2020; 29: 1316-8; https://doi.org/10.1002/pds.5010
Schünemann , Brożek J, Guyatt G, et al. GRADE Handbook. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. Available at: https://gdt.gradepro.org/app/handbook/handbook.html (last accessed on January 2022)
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
